Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab long-term extension study in multiple myeloma
2022-500138-27-01Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Planned start Feb 2023; status: authorised.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-500138-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500138-27-01.